Clinical use of I.C.I. 50172 as an antidysrhythmic agent in heart failure.
I.C.I. 50172 was used to slow the ventricular rate when conventional treatment had failed in 19 patients. All were either in congestive cardiac failure or in the immediate postoperative period following valve replacement. The ventricular rate was controlled in seven out of eight patients with atrial fibrillation, in six out of nine patients with supraventricular tachycardia, and in two patients with sinus rhythm. Important side-effects were not seen.
D001281:Atrial Fibrillation / Q000188:drug therapy; D002302:Cardiac Output; D004554:Electric Countershock; D004562:Electrocardiography; D006329:Heart Conduction System / Q000187:drug effects; D006333:Heart Failure / Q000188:drug therapy*; D006339:Heart Rate / Q000187:drug effects; D006801:Humans; D013565:Sympatholytics / Q000009:adverse effects / Q000627:therapeutic use*; D013610:Tachycardia / Q000188:drug therapy*
D013565:Sympatholytics